Is 12 nmol/L testosterone really a treatment threshold?
Quick answer
At 12 nmol/L, a man falls within the gray zone defined by European andrology guidelines, where the presence and severity of symptoms should guide whether further workup for hypogonadism is warranted. Diagnosis requires at least two morning total testosterone measurements plus assessment of free testosterone and pituitary hormones before any treatment decision. Reversible secondary causes of low testosterone should be excluded before initiating TRT.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @ali_on_t actually say?
The creator told a follower that "if you have symptoms" at 12 nmol/L, you "should probably be looking to see if you're appropriate for treatment." That's a reasonable summary of a genuinely contested clinical question. They didn't prescribe a dose, didn't name a drug, and didn't promise a cure. The framing was conditional, which matters a lot here.
Worth noting: the auto-caption rendered "nmol" as "animals per liter," which is a transcription error, not something the creator said. The caption itself spells it out correctly as 12 nmol/L. Judging the spoken content on that mangled transcript would be unfair.
The core claim is that 12 nmol/L plus symptoms is a situation worth investigating clinically. That's not the same as saying everyone at 12 nmol/L should start testosterone. The "if" is doing real work in that sentence.
Does the science back this up?
Mostly, yes. The threshold question in male hypogonadism is one of the messier corners of endocrinology, and 12 nmol/L sits right in the middle of the debate.
The European Academy of Andrology and the European Society of Endocrinology define biochemical hypogonadism as total testosterone below 12 nmol/L, with a gray zone between 8 and 12 nmol/L where symptoms should drive the clinical decision (Dohle et al., 2012, European Urology). The American Urological Association uses 300 ng/dL (roughly 10.4 nmol/L) as its cutoff, which is slightly lower (Mulhall et al., 2018, Journal of Urology). Neither organization draws a hard line and ignores symptoms.
Bhasin et al. (2010, Journal of Clinical Endocrinology and Metabolism) confirmed that testosterone thresholds for symptom onset vary considerably between individuals. Some men are symptomatic at 12 nmol/L. Some aren't symptomatic at 8. The creator's framing, that symptoms matter alongside the number, reflects actual clinical guidance.
What did they get wrong (or right)?
They got the core logic right. A number alone doesn't justify treatment, and symptoms alone don't either. Combining both, and then suggesting evaluation rather than immediately starting therapy, is the responsible framing here.
What's missing is context that matters. A single total testosterone measurement at 12 nmol/L isn't enough to make any decision. Guidelines from the Endocrine Society (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) require at least two morning measurements on separate days, plus evaluation of free testosterone, luteinizing hormone, FSH, and prolactin before any diagnosis of hypogonadism. The creator didn't mention any of this, which could leave viewers thinking one blood test reading settles the question.
There's also no mention of reversible causes. Sleep apnea, obesity, opioid use, and chronic illness can suppress testosterone. Treating the underlying cause sometimes resolves low levels without TRT. A TikTok directing someone straight toward "exploring treatment" skips that step, even if it doesn't explicitly recommend testosterone.
What should you actually know?
If your testosterone comes back at 12 nmol/L and you feel lousy, you are not automatically a candidate for TRT, but you are a candidate for a proper workup. Those are different things.
The gray zone between 8 and 12 nmol/L is where clinicians are supposed to use judgment, not a calculator. Symptoms of low testosterone, including fatigue, low libido, poor concentration, and reduced muscle mass, overlap with dozens of other conditions. Depression, thyroid dysfunction, and anemia can produce identical symptoms with completely normal testosterone. A clinician who jumps to TRT without ruling those out is not doing their job.
If you do end up being a genuine candidate, the Endocrine Society recommends starting with a shared decision-making conversation that covers what TRT can and cannot do, the fertility implications (exogenous testosterone suppresses sperm production), and the fact that long-term cardiovascular data is still accumulating (Lincoff et al., 2023, New England Journal of Medicine, found no excess short-term major cardiovascular events, but longer follow-up is ongoing).
The creator's advice to "explore treatment" is defensible. The gap is everything that should happen in that exploration that a 15-second TikTok can't cover.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 11 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Is 12 nmol/L testosterone really a treatment threshold?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Is 12 nmol/L testosterone really a treatment threshold? should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
At 12 nmol/L, a man falls within the gray zone defined by European andrology guidelines, where the presence and severity of symptoms should guide whether further workup for hypogonadism is warranted.
FormBlends verdict
At 12 nmol/L, a man falls within the gray zone defined by European andrology guidelines, where the presence and severity of symptoms should guide whether further workup for hypogonadism is warranted. Diagnosis requires at least two morning total testosterone measurements plus assessment of free testosterone and pituitary hormones before any treatment decision. Reversible secondary causes of low testosterone should be excluded before initiating TRT.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- At 12 nmol/L, a man falls within the gray zone defined by European andrology guidelines, where the presence and severity of symptoms should guide whether further workup for hypogonadism is warranted. Diagnosis requires at least two morning total testosterone measurements plus assessment of free testosterone and pituitary hormones before any treatment decision. Reversible secondary causes of low testosterone should be excluded before initiating TRT.
- European andrology guidelines define the gray zone for testosterone as 8-12 nmol/L, where symptoms should guide the clinical decision, not the number alone (Dohle et al., 2012, European Urology).
- The Endocrine Society requires at least two separate morning testosterone measurements before diagnosing hypogonadism. One result at 12 nmol/L is not a diagnosis.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- European andrology guidelines define the gray zone for testosterone as 8-12 nmol/L, where symptoms should guide the clinical decision, not the number alone (Dohle et al., 2012, European Urology).
- The Endocrine Society requires at least two separate morning testosterone measurements before diagnosing hypogonadism. One result at 12 nmol/L is not a diagnosis.
- Free testosterone matters as much as total. A man with 12 nmol/L total but low sex hormone-binding globulin may have adequate free testosterone and no clinical hypogonadism.
- Reversible causes including sleep apnea, obesity, opioid use, and chronic illness can lower testosterone. These should be ruled out before considering TRT.
- The 2023 TRAVERSE trial (Lincoff et al., New England Journal of Medicine) found no significant increase in major cardiovascular events with TRT over roughly 22 months in middle-aged men with hypogonadism, but longer-term data is still being collected.
- TRT suppresses the hypothalamic-pituitary-gonadal axis and reduces sperm production. Men who want future biological children need a separate fertility conversation before starting.
- The AUA cutoff for low testosterone is 300 ng/dL (approximately 10.4 nmol/L), slightly lower than the European threshold, which means guidelines from different bodies give somewhat different answers on the same number.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Ali on T · TikTok creator
6.1K views on this video
Replying to @fabilousmusic You should be exploring treatment if your levels are 12nmol and you have symptoms #TRT #TestosteroneReplacementTherapy #testosteronelevels #bodybuilding
Sources & references
- [1]Dohle et al., 2012
- [2]Mulhall et al., 2018
- [3]Bhasin et al. (2010)
- [4]Bhasin et al., 2018
- [5]Lincoff et al., 2023
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Ali on T, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.